ResMed (RMD) Tops Q2 EPS by 22c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ResMed (RMD) Gains Over 17% on FQ2 Earnings Beat, Ratings Upgrades and Price Target Boost
January 23, 2018 12:13 PM ESTResMed (NYSE: RMD) is seeing buyers bid up shares today, gaining 17% on the session, after the company reported fiscal second quarter earnings per share and revenue figures above consensus, last night after the close.
Analysts on Wall Street responded to the company's... More
Northland Capital Markets Upgrades ResMed (RMD) to Market Perform
January 23, 2018 8:50 AM ESTNorthland Capital Markets upgraded ResMed (NYSE: RMD) from Underperform to Market Perform with a price target of $80.00.
Analyst Suraj Kalia comments "While our core thesis on price erosion has been right, with organic GM' down ~700 bps over last 3 yrs & net mgns down ~ 500 bps;... More
Needham & Company Upgrades ResMed (RMD) to Hold
January 23, 2018 7:34 AM ESTNeedham & Company upgraded ResMed (NYSE: RMD) from Underperform to Hold.
Analyst Mike Matson commented, "RMD's revenue and EPS both significantly beat consensus in F2Q18. Organic revenue growth improved to 11% in F2Q18 from 10% in F1Q18 as RMD saw both stronger... More
ResMed (RMD) PT Raised to $76 at Barclays
January 23, 2018 5:18 AM ESTBarclays raised its price target on ResMed (NYSE: RMD) to $76.00 (from $70.00) while maintaining a Underweight rating.
... More